n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, September 29th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Orgenesis, Inc. (ORGS)

IRGnews Alert, SmallCapNetwork, OTCPicks, Stock News Now, Greenbackers, Streetwise Reports, and pastwellness reported earlier on Orgenesis, Inc. (ORGS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Orgenesis, Inc. is a fully-integrated cell therapy and contract development and manufacturing company. It has a novel therapeutic technology for the treatment of diabetes. The Company has expertise and unique experience in cell therapy development and manufacturing. OTCQB-listed, Orgenesis is based in Germantown, Maryland.

In addition, the Company has a fully-owned subsidiary contract manufacturing and development company -  MaSTherCell S.A. (Belgian subsidiary). This subsidiary’s dedication is to cell therapy for advanced medicinal products. MaSTherCell (a full-service contract development and manufacturing organization (CDMO)) specializes in the delivery of optimized process industrialization capacities to cell therapy organizations 

Furthermore, by way of its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). 

Orgenesis has a novel therapeutic approach in the treatment of diabetes through correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. The Company uses a molecular and cellular approach directed at transforming liver cells into functional insulin-producing cells as a treatment for diabetes. The new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.

Through its Israeli subsidiary, Orgenesis continues to advance its innovative cell-based therapy, the Autologous Insulin Producing (AIP) cells, into clinical development.  AIP cells use the technology of 'cellular transdifferentiation' to transform an autologous adult liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell. 

Orgenesis has demonstrated promising results in in-vitro and in-vivo studies using human liver tissues. It designed an efficient and clear work-plan to start clinical testing soon, allowing it to launch Phase I clinical trials following Food and Drug Administration (FDA) guidelines followed by the launch of Phase II clinical trials within a year.

In 2016, Orgenesis entered into a number of strategic partnerships and joint venture (JV) agreements. It entered into a JV Agreement with CureCell; it is collaborating in the contract development and manufacturing of cell therapy products in Korea.

Orgenesis Ltd, its Israeli subsidiary, entered into a pharma Cooperation and Project Funding Agreement (CPFA) with KORIL and CureCell in 2016. KORIL will provide funding for a joint research and development project for the use of AIP cells for the treatment of diabetes.

Orgenesis also entered into a JV agreement with Atvio Biotech Ltd., an Israeli company. This agreement is to collaborate in the contract development and manufacturing of cell and virus therapy products in the field of regenerative medicine.

Orgenesis, Inc. (ORGS), closed Friday's trading session at $0.45, even for the day. The average volume for the last 60 days is 33,304 and the stock's 52-week low/high is $0.28/$0.98.

Intellinetics, Inc. (INLX)

OTC Markets reported on Intellinetics, Inc. (INLX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Intellinetics, Inc. is an Enterprise Content Management (ECM) Software Company listed on the OTC Markets Group’s OTCQB. The Company is a provider of a cloud-enabled document management platform – IntelliCloud™ – optimized for the huge Small to Medium Business (SMB) market segment and business teams within large enterprises. Formed in 1994, Intellinetics has its headquarters in Columbus, Ohio

Intellinetics concentrates on cloud-based document solutions for the SMB market. The Company partnered with Intel to create the IntelliCloud Channel Program. This program makes it easy to add turnkey document workflow solutions to the copiers, productivity software and services they already provide.

Intellinetics’ cloud-based computing software is customizable for every client. This makes it applicable to almost any industry. Intellinetics provides a low-cost delivery model. This permits quick implementation and reduced storage requirements.

IntelliCloud provides dealers a “deploy once, use many” innovation. One IntelliCloud customer sale/activation creates unlimited possibilities to add other software applications that deliver greater value and increase revenue.

The IntelliCloud™ Document Workflow Management suite allows Small and Midsize Enterprises (SMEs) to easily capture paper or digital documents and connect them to business processes to decrease costs. This is while increasing accessibility, security, and compliance.

Intellinetics’ emphasis is on IntelliCloud Program growth within three specific partner profiles. One is Office Equipment Dealers (OED) - Copier dealers who also provide value added software, service, and technology services. The second is ECM Value Added Reseller (VAR) - Expert ECM software, hardware and service providers. The third is Software Solution Providers - Enterprise Resource Planning (ERP) or other software applications with proprietary IntelliCloud Integration.

Intellinetics has integrated its IntelliCloud™ platform with Field2Base’s industry-leading Field Service Automation (FSA) suite. The combined solution joins in-field and back-office documents and workflow. This creates an end-to-end process letting customers of any size to truly go paperless in the field.

This week, Intellinetics announced that its Board of Directors appointed Mr. James F. DeSocio as President & Chief Executive Officer (CEO), effective September 25, 2017. In addition, Mr. DeSocio was appointed to the Board of Directors of Intellinetics, effective the same day.

Mr. Matthew L. Chretien, the former President and CEO assumed the role of Chief Strategy Officer on September 25, 2017. He retains his roles as Chief Technology Officer and a member of the Intellinetics' Board of Directors.

Intellinetics, Inc. (INLX), closed Friday's trading session at $0.30, even for the day, on 8 volume with 2 trades. The average volume for the last 60 days is 37,032 and the stock's 52-week low/high is $0.13/$0.9975.

RegeneRx Biopharmaceuticals, Inc. (RGRX)

Stock News Now, TopPennyStockMovers, PennyStockProphet, Penny Pick Finders, Planet Penny Stocks, Buzz Stocks, Stock Onion, and SmarTrend Newsletters reported previously on RegeneRx Biopharmaceuticals, Inc. (RGRX) and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company. It concentrates on tissue protection, repair, and regeneration with a comprehensive portfolio of product candidates for first-in-class therapeutic peptides. The Company’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma, or other pathology. RegeneRx Biopharmaceuticals is based in Rockville, Maryland. 

RegeneRx holds numerous issued patents or filed patent applications internationally to enable and protect multiple indications and applications for its product candidates. Currently, the Company has three drug candidates in clinical development for ophthalmic, cardiac, and dermal indications. In addition, it has three active strategic licensing agreements in the United States, China, and Pan Asia (Korea, Japan, and Australia, among others). RegeneRx also has patents and patent applications covering its products in many nations worldwide. 

The Company is focusing on moving three distinct Tβ4-based drug candidates through the clinic. These are RGN-137, RGN-259, and RGN-352. RGN-137 is a topical gel formulation of the peptide Tβ4. RegeneRx is developing this as a novel treatment to hasten dermal healing. RGN-137 is a Tβ4-based dermal gel formulation undergoing development for epidermolysis bullosa, which is a rare skin condition.

RegeneRx is also developing RGN-352. RGN-352 is its TB4-based injectable. This is a Phase 2-ready drug candidate designed to be administered systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue damage associated disorders. These include peripheral neuropathy, multiple sclerosis and traumatic brain injuries - including stroke.

RegeneRx Biopharmaceuticals is centering on the development of Thymosin beta 4 (a novel therapeutic peptide), for tissue and organ protection, repair and regeneration. RGN-259, its TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a main emphasis of the Company's clinical development efforts in the U.S.

This past July, RegeneRx, via its U.S joint venture (JV), ReGenTree LLC, completed patient enrolment and treatment in its second Phase 3 clinical trial in around approximately 600 patients with dry eye syndrome.  Additionally, the Company is at the same conducting a 46-patient Phase 3 clinical trial in patients with NK, targeted for completion in 2018. Also, RGN-259 is undergoing development in patients with dry eye syndrome in Asia by way of RegeneRx's two Asian partnerships.  

At the end of August, RegeneRx Biopharmaceuticals announced it completed a license expansion agreement with GtreeBNT for the rights to RGN-137, RegeneRx's topical gel formulation of thymosin beta 4 (Tβ4), in Europe, South Korea, Japan, Canada, and Australia.

Earlier this month, RegeneRx announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for Thymosin beta 4 (Tβ4) for use in the treatment of dry eye syndrome.  Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-259. This is a first-in-class product candidate designed for topical administration to patients suffering from dry eye syndrome.

RegeneRx Biopharmaceuticals, Inc. (RGRX), closed Friday's trading session at $0.33, down 0.60%, on 29,500 volume with 10 trades. The average volume for the last 60 days is 83,027 and the stock's 52-week low/high is $0.22/$0.3979.

Alpine 4 Technologies Ltd. (ALPP)

OTC Markets, InvestorsHub, Stockhouse TradingView, and MarketWatch reported on Alpine 4 Technologies Ltd. (ALPP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Alpine 4 Technologies Ltd. is a  technology and manufacturing holding enterprise. It has business-related endeavors in Automotive Technologies, Electronics Manufacturing, Software and Energy Services. Alpine 4 Technologies has its corporate office in Phoenix, Arizona.

The Company’s focus is on how the adaptation of new technologies, even in brick and mortar businesses, can boost innovation. The heart of Alpine 4 Technologies’ acquisition strategy is its concentration on existing smaller middle market operating companies with revenues of $5 to $50 million.

The design of Alpine 4 is to allow its subsidiaries room to develop their own identities and synergistically prosper from inter-company resources and collaboration.  Alpine 4 will own controlling interest in every subsidiary. Furthermore it will have direct control over planning and management.
  
Regarding the Company’s subsidiaries and product groups, these include 6th Sense Auto; BrakeActive™; Quality Circuit Assembly; and Venture West Energy Services. 6th Sense Auto is an automotive technology division of Alpine 4. This division provides a distinct and strong advantage to management, sales, finance and service departments at automotive dealerships.

BrakeActive™ is a safety device. It improves a vehicle’s third brake lights ability to considerably lessen or prevent a rear end collision by up to 40 percent. Alpine 4’s Quality Circuit Assembly subsidiary provides electronic contract manufacturing solutions delivered to its customers via strategic business partnerships. In addition, Venture West Energy Services concentrates on supporting the oil and gas industry in Texas, Oklahoma, and Arkansas.

Recently, Alpine 4 Technologies announced that it entered into a Letter of Intent (LOI) to acquire all of the outstanding securities of Lattice Incorporated and Letters of Intent with certain of Lattice's creditors to convert their debt in Lattice into equity. The companies expect the transaction to close by the end of this calendar year.
Lattice is a trusted international partner to correctional facilities. It provides a total range of unique inmate management and communications solutions. These solutions deliver greater efficiencies to facilities, reduce the administrative burden on their staff, provide them with revenue-generating opportunities, and connect their inmates with family and friends. Lattice serves roughly 350 correctional facilities and more than 78,000 inmates in the U.S., Canada, Japan, and Europe.

At the end of August, Alpine 4 Technologies announced that its subsidiary ALTIA reached an agreement with the Future Automotive Group, and their Future Ford of Sacramento and Future Ford of Roseville dealerships.  The agreement uses the 6th Sense Auto platform for inventory management, customer retention, as well as resale as an aftermarket connected car product. 6th Sense Auto is committed to assisting large dealerships improve their inventory management, engine diagnostics, service maintenance, and personalized customer support services by way of wireless, cloud-based software.

Alpine 4 Technologies Ltd. (ALPP), closed Friday's trading session at $0.16, down 0.64%, on 800 volume with 1 trade. The average volume for the last 60 days is 14,265 and the stock's 52-week low/high is $0.09/$14.00.

Dais Analytic Corp. (DLYT)

StockEgg, StockRich, Stockpalooza, Money Morning, Penny Stock Rumble, FeedBlitz, M2 Communications, HotOTC, SmallCap Pulse, BullRally, SmallCapVoice, CoolPennyStocks, MadPennyStocks, PennyInvest, PennyStockVille, and Greenbackers reported previously on Dais Analytic Corp. (DLYT), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Dais Analytic Corp sells its industry-changing nanomaterial technology into the worldwide water, air, and energy markets. A commercial nanotechnology materials business, the Company provides nanotechnology-based applications for heating & cooling, water treatment, and energy storage. It is commercializing its inventive Aqualyte™ family of nano-structured materials and processes focusing on disruptive air, energy, and water applications. Dais Analytic is based in Odessa, Florida.  

The uses of the Aqualyte™ family of nano-structured materials and processes include ConsERV™. This is a commercially available engineered energy recovery ventilator (a heating, ventilation, and air conditioning (HVAC) product). Additionally, the uses include NanoAir™. This is an early beta-stage water-based, no fluorocarbon producing refrigerant cooling cycle. 

Uses also include NanoClear™. This is an early beta-stage method for treating contaminated water to provide 1,000 times cleaner potable water. The NanoClear™ process has consistently shown that Dais Analytic’s novel Aqualyte® material can separate most contaminants from water, attaining almost 'parts per billion' clean product water with little or no fouling of the vital membrane component. 

NanoClear™ is a cutting-edge water cleaning architecture enabled by the features in the Company’s nanomaterial - Aqualyte™. The NanoClear™ product line is a vital application in purifying contaminated water having high salt content, low pH, or where the need for Total Dissolved Solid (TDS) in the product water is 10 or less. 

Uses also include NanoCAP™. Dais indicates that NanoCAP™ holds promise to use the Aqualyte™ family to form a disruptive, non-chemical, energy-storage device (an ultra-capacitor) when completed for use in transportation, renewable energy, as well as 'smart grid' configurations. 

In June 2017, Dais Analytic announced that it delivered its initial Environmental Navigator™ System in China. The Company also signed up its first new in-country Distributor who has started selling this new advanced product. The Environmental Navigator considerably improves Indoor Air Quality (IAQ) by providing fresh, filtered air with less airborne particles in the indoor space.

The Environmental Navigator utilizes Dais Analytic's award-winning ConsERV™ Energy Recovery Ventilator technology to precondition this fresh air, delivering up to 70 percent energy savings managing ventilation air and in numerous situations the ability to downsize the HVAC plant size by up to a 1/3rd.

Recently, Dais Analytic announced it signed a 7 year, non-exclusive agreement with the Menred Group, Zhejiang province, China. This agreement is to provide its Aqualyte moisture transfer nanomaterial for use in a newer line of Menred energy recovery ventilators (ERV) to sell into the rising Chinese heating, ventilation and air conditioning (HVAC) market.

Dais Analytic Corp. (DLYT), closed Friday's trading session at $0.0221, down 13.33%, on 3,455 volume with 1 trade. The average volume for the last 60 days is 51,255 and the stock's 52-week low/high is $0.015/$0.20.

graphic

The QualityStocks
Company Corner

graphic
graphic

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.07, up 2.64%, on 5,005,159 volume with 352 trades. The stock’s average daily volume over the past 60 days is 4,409,457, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding, Inc.(OTC PINK: POTN) is pleased to announce that the Company, in partnership with Dank City, LLC, a leading social and digital media platform for medical cannabis patients and businesses, was selected as the exclusive Premier Sponsor of Tommy Chong's Blazer's Cup, a large cannabis festival held in San Bernardino, CA on December 2 and 3, 2017.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

Diamond CBD to Sponsor Tommy Chong's Blazer's Cup Presented in San Bernadino in Partnership with Dank City LLC

PotNetwork Holding, Inc. Launches Storewide Discount on Diamond CBD Products to Support Recovery Efforts by Contributing 10% of Revenues over the Next 3 Days to Community Restoration Projects

PCAOB Registered CPA Firm Engaged to Initiate Audit on PotNetwork Holding, Inc.’s Recent Revenues

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.47, up 6.89%, on 202,466 volume with 117 trades. The stock’s average daily volume over the past 60 days is 87,819 and its 52-week low/high is $0.33/$2.75.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products. The publication is titled, "Cannabis Companies Demonstrate the Diverse Nature of the Global Marijuana Market." It discusses various public companies across multiple sectors that are getting their share of the profitable marijuana market. To view the full publication, visit: https://www.networknewswire.com/cannabis-companies-demonstrate-diverse-nature-global-marijuana-market/

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

ChineseInvestors.com, Inc. Announces Paul Dickman's Return as its Chief Financial Officer

NetworkNewsWire Announces Publication on Cannabis Industry Forecasts and Public Companies Advancing in the Market

Alan Klitenic, Director of Investor Relations for ChineseInvestors.com, Discusses Recent CIIX News and Industry Trends in a New Audio Interview with SmallCapVoice.com

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.40, even for the day, on 596,562 volume with 272 trades. The stock’s average daily volume over the past 60 days is 429,650, and its 52-week low/high is $0.08/$0.72.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. The publication, titled, "Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development," discusses companies on a mission to find the next groundbreaking technology targeting cannabinoids. To view the full publication, visit: https://www.networknewswire.com/cannabinoid-biosynthesis-poised-potential-game-changer-drug-development/

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication Highlighting Companies Engaged in Advanced Cannabinoid Research

NetworkNewsWire Announces Publication Highlighting Unique Technology in Cannabinoid-Based Medicine

NetworkNewsWire Announces Publication on Advances in Cannabinoid-Based Medicine

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.11, up 14.11%, on 47,300 volume with 6 trades. The stock’s average daily volume over the past 60 days is 11,823 and its 52-week low/high is $0.0001/$0.62.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp Enters Into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products; Accelerates Go-to-Market Strategy

NetworkNewsWire Releases Exclusive Audio Interview with Algae Dynamics Corp. (ADYNF)

Algae Dynamics Corp. (ADYNF) Engages NetworkNewsWire for Corporate Communications Solutions

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.485, up 7.78%, on 104,716 volume with 50 trades. The stock’s average daily volume over the past 60 days is 100,164 and its 52-week low/high is $0.1101/$0.699.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication Highlighting Recent Developments in Drug Delivery Technologies

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria's TurboCBD

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Journal Transcript
(XXFPL) +700.00%

2.

BUYINS.NET
(ZGNX) +172.23%

3.

ProTrader
(ICNN) +57.09%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251